On Monday, a team of researchers at UNC-Chapel Hill, in conjunction with colleagues at Vanderbilt University, Emory University, and the Centers for Disease Control and Prevention, announced a ...

MIAMI--(BUSINESS WIRE)--Ridgeback Biotherapeutics announces the launch of two Phase 2 clinical trials to test the efficacy of EIDD-2801 as an anti-viral treatment for COVID-19. Phase 1 trials recently ...

As the COVID-19 pandemic shut down much of the world, George Painter’s life geared up considerably. In a matter of weeks, Painter and his collaborators have seen the antiviral they were working ...

CHAPEL HILL, N.C. (WTVD) -- Scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health say an orally administered experimental drug has proven effective at preventing and ...

Click or touch the map to see cases in the North Carolina area. Pan the map to see cases elsewhere in the US. The data for the map is maintained by the Center for Systems Science and Engineering at ...

EIDD-2801, one of the most promising coronavirus antiviral drugs, just lept ahead of the pack. Merck has partnered with Ridgeback Biologics to develop the drug. It has a lot going for it. Here's why.

MIAMI--(BUSINESS WIRE)--Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801. The new trial will be conducted using the new COVID-19 ...

Last week, Merck and Ridgeback Biotherapeutics announced Phase 3 results of molnupiravir, an oral antiviral drug, in patients with mild-to-moderate Covid-19. In a trial that included more than 750 ...

(RTTNews) - Merck & Co. Inc. (MRK) said that it has reached a collaboration agreement with Ridgeback Biotherapeutics LP to develop EIDD-2801, an orally available antiviral candidate currently in early ...